Document Detail

Ranitidine in the prevention of gastroduodenal damage during antiblastic polychemotherapy.
MedLine Citation:
PMID:  16498377     Owner:  NLM     Status:  PubMed-not-MEDLINE    
BACKGROUND: The authors report their personal experience of the use of ranitidine in the prevention of gastroduodenal damage induced by antiblastic drugs during antiblastic polychemotherapy. METHODS: A heterogeneous group of cancer patients was monitored from January 1984 to December 1999 (293 males and 204 females), aged between 36 and 80 years old, a11 of whom were undergoing antineoplastic polychemotherapy. Preventive treatment with ranitidine at a dose of 300 mg/die per os in a single evening bolus continued through the entire period of antiblastic treatment ranging from a minimum of six months to one year or more. The study was carried out in the General Surgery Department of Valdichiana Senese, Local Health Unit 7 in Siena and in the Department of Surgical Oncology at the University of Catania. The study consisted of a clinical and instrumental follow-up using esophagogastroduodenoscopy at the time patients were enrolled and at 3, 6 and 12 months, or at the end of treatment if longer. RESULTS: Ranitidine was useful and could significantly reduce the harmful gastric effects of antiblastic drugs, as has been extensively shown by the literature. These drugs can lead to the suspension of treatment owing to intolerance or even death. In this study ranitidine reduced the damaging effects on the upper digestive tract in respectively 78% of the cases treated compared to 22% of non-responders. CONCLUSIONS: The action of ranitidine made antiblastic treatment more acceptable by mitigating or even blocking the damaging effects on the stomach and duodenum, leading to an improved quality of life for cancer patients.
A D'Agata; M Berretta; S Sensi; S Berretta
Related Documents :
22902147 - Additional endovascular therapy in patients with acute ischemic stroke who are nonrespo...
7585847 - Comparison of gastric mucosal surface ph response times after intravenous administratio...
18184117 - A randomized, comparative trial of a potassium-competitive acid blocker (azd0865) and e...
2892257 - 300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ...
12144187 - Results of curative therapy for esophageal cancer in a community training hospital.
9420337 - Relation between therapy for hyperthyroidism and the course of graves' ophthalmopathy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva gastroenterologica e dietologica     Volume:  46     ISSN:  1121-421X     ISO Abbreviation:  Minerva Gastroenterol Dietol     Publication Date:  2000 Sep 
Date Detail:
Created Date:  2006-02-24     Completed Date:  2006-03-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9109791     Medline TA:  Minerva Gastroenterol Dietol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  155-64     Citation Subset:  -    
Department of General Surgery Valdichiana Senese, Surgical Oncology and Clinical Therapy, Local Health Unit N. 7--Siena.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Night eating in severely obese patients
Next Document:  Treatment of primary biliary cirrhosis.